Valproic acid regulates α-synuclein expression through JNK pathway in rat primary astrocytes

Biomolecules and Therapeutics

Volumn 21, Issue 3, 2013, Pages 222-228

  Kim, Jung Nam ^a   Kim, Min Kyeong ^a   Cho, Kyu Suk ^a   Choi, Chang Soon ^a   Park, Seung Hwa ^a   Yang, Sung Il ^a   Joo, So Hyun ^a   Park, Jin Hee ^a   Bahn, Geonho ^b   Shin, Chan Young ^a   Lee, He Jin ^a   Han, Seol Heui ^a   Kwon, Kyoung Ja ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

synuclein; Acetylation; JNK; Neuroprotection; Stability; Valproic acid

Indexed keywords

ALPHA SYNUCLEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; VALPROIC ACID;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT;

RATTUS;

EID: 84878469679     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2013.006     Document Type: Article

References (41)

1. Alves Da Costa, C., Paitel, E., Vincent, B.and Checler, F.(2002) Al- pha-synuclein lowers p53-dependent apoptotic response of neuronal cells.Abolishment by 6-hydroxydopamine and implication for Parkinson's disease.J.Biol.Chem.277, 50980-50984.
2. Bennett, M.C., Bishop, J.F., Leng, Y., Chock, P.B., Chase, T.N.and Mouradian, M.M.(1999) Degradation of alpha-synuclein by pro- teasome.J.Biol.Chem.274, 33855-33858.
3. Björkblom, B., Padzik, A., Mohammad, H., Westerlund, N., Komulainen, E., Hollos, P., Parviainen, L., Papageorgiou, A.C., Iljin, K., Kallioniemi, O., Kallajoki, M., Courtney, M.J., Mágárd, M., James, P.and Coffey, E.T.(2012) c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells.Mol.Cell.Biol.32, 3513-3526.
4. Cao, C., Lu, S., Kivlin, R., Wallin, B., Card, E., Bagdasarian, A., Tamakloe, T., Wang, W.J., Song, X., Chu, W.M., Kouttab, N., Xu, A.and Wan, Y.(2009) SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes.J.Cell.Mol.Med.13, 3632-3643.
5. Catalano, M.G., Poli, R., Pugliese, M., Fortunati, N.and Boccuzzi, G., (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.Endocr.Relat.Cancer 14, 839-845.
6. Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M.L., Sola, F., Cappella, P., Perrera, C., Depaolini, S.R., Rusconi, L., Cucchi, U., Avanzi, N., Bertrand, J.A., Bossi, R.T., Pesenti, E., Galvani, A., Isacchi, A., Colotta, F., Donati, D.and Moll, J.(2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.Cancer Res.70, 10255-10264.
7. Einat, H., Yuan, P., Gould, T.D., Li, J., Du, J., Zhang, L., Manji, H.K.and Chen, G.(2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.J.Neurosci.23, 7311-7316.
8. Geng, H., Liu, Q., Xue, C., David, L., Beer, T.M., Thomas, G.V., Dai, M.S.and Qian, D.Z.(2012) HIF1 a protein stability is increased by acetylation at lysine-K709.J.Biol.Chem.287, 35496-35505.
9. Glozak, M.A., Sengupta, N., Zhang, X.and Seto, E.(2005) Acetylation and deacetylation of non-histone proteins.Gene 363, 15-23.
10. Jensen, P.J., Alter, B.J.and O'Malley, K.L.(2003) Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity.J.Neurochem.86, 196-209.
11. Joo, S.H., Kwon, K.J., Kim, J.W., Hasan, M.R., Lee, H.J., Han, S.G.and Shin, C.Y.(2010) Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells.Neurosci.Lett.469, 352-356.
12. Kanai, H., Sawa, A., Chen, R.W., Leeds, P.and Chuang, D.M.(2004) Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons.Pharmacogenomics J.4, 336-344.
13. Kang, S.A., Na, H., Kang, H.J., Kim, S.H., Lee, M.H.and Lee, M.O.(2010) Regulation of Nur77 protein turnover through acetylation and deacetylation induced by p300 and HDAC1.Biochem.Pharmacol.80, 867-873.
14. Karpinar, D.P., Balija, M.B., Kügler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., Kim, H.Y., Taschenberger, G., Falkenburger, B.H., Heise, H., Kumar, A., Riedel, D., Fichtner, L., Voigt, A., Braus, G.H., Giller, K., Becker, S., Herzig, A., Baldus, M., Jäckle, H., Eimer, S., Schulz, J.B., Griesinger, C.and Zweckstetter, M.(2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.EMBO J.28, 3256-3268.
15. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A.and Yao, T.P.(2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.Cell 115, 727-738.
16. Kim, S.H., Kang, H.J., Na, H.and Lee, M.O.(2010) Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein.Breast Cancer Res.12, R22.
17. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols, L.and Riess, O.(1998) Ala- 30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.Nat.Genet.18, 106-108.
18. Lee, H.J., Patel, S.and Lee, S.J.(2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates.J.Neurosci.25, 6016-6024.
19. Lee, H.J., Shin, S.Y., Choi, C., Lee, Y.H.and Lee, S.J.(2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.J.Biol.Chem.277, 5411-5417.
20. Leng, Y.and Chuang, D.M.(2006) Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excito- toxicity.J.Neurosci.26, 7502-7512.
21. L'Episcopo, F., Tirolo, C., Testa, N., Caniglia, S., Morale, M.C.and Marchetti, B.(2010) Glia as a turning point in the therapeutic strategy of Parkinson's disease.CNS Neurol.Disord.Drug Targets 9, 349-372.
22. Li, K., Wang, R., Lozada, E., Fan, W., Orren, D.K.and Luo, J.(2010) Acetylation of WRN protein regulates its stability by inhibiting ubiq- uitination.PloS One 5, e10341.
23. Marchetti, B.(1997) Cross-talk signals in the CNS: Role of neuro- trophic and hormonal factors, adhesion molecules and intercellular signaling agents in luteinizing hormone-releasing hormone (LHRH) neuron-astroglia interactive network.Front.Biosci.2, d88-d125.
24. Monti, B., Gatta, V., Piretti, F., Raffaelli, S.S., Virgili, M.and Contestabile, A.(2010) Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.Neurotox.Res.17, 130-141.
25. Monti, B., Polazzi, E.and Contestabile, A.(2009) Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.Curr.Mol.Pharmacol.2, 95-109.
26. Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, F.A., Nicoll, R.A.and Edwards, R.H.(2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.Neuron 65, 66-79.
27. Park, J.Y., Paik, S.R., Jou, I.and Park, S.M.(2008) Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.Glia 56, 1215-1223.
28. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropou- los, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di, I.G., Golbe, L.I.and Nussbaum, R.L.(1997) Mutation in the alpha- synuclein gene identified in families with Parkinson's disease.Science 276, 2045-2047.
29. Seo, J.H., Rah, J.C., Choi, S.H., Shin, J.K., Min, K., Kim, H.S., Park, C.H., Kim, S., Kim, E.M., Lee, S.H., Lee, S., Suh, S.W.and Suh, Y.H.(2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway.FASEB J.16, 1826-1828.
30. Shin, C.Y., Choi, J.W., Jang, E.S., Ryu, J.H., Kim, W.K., Kim, H.C.and Ko, K.H.(2001) Glucocorticoids exacerbate peroxynitrite mediated potentiation of glucose deprivation-induced death of rat primary astrocytes.Brain Res.923, 163-171.
31. Sidhu, A., Wersinger, C.and Vernier, P.(2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J.18, 637-647.
32. Singh, B.N., Zhang, G., Hwa, Y.L., Li, J., Dowdy, S.C.and Jiang, S.W.(2010) Nonhistone protein acetylation as cancer therapy targets.Expert Rev.Anticancer Ther.10, 935-954.
33. Sofroniew, M.and Vinters, H.B.(2010) Astrocytes: biology and pathology.Acta Neuropathol.119, 7-35.
34. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R.and Goedert, M.(1997) Alpha-synuclein in Lewy bodies.Nature 388, 839-840.
35. Su, M., Shi, J.J., Yang, Y.P., Li, J., Zhang, Y.L., Chen, J., Hu, L.F.and Liu, C.F.(2011) HDAC6 regulates aggresome-autophagy degradation pathway of alpha-synuclein in response to MPP+-induced stress.J.Neurochem.117, 112-120.
36. Tönges, L., Planchamp, V., Koch, J.C., Herdegen, T., Bähr, M.and Lingor, P.(2011) JNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro.J.Mol.Neurosci.45, 284-293.
37. Ushijima, H.and Maeda, M.(2012) cAMP-dependent proteolysis of GATA-6 is linked to JNK-signaling pathway.Blochem.Biophys.Res.Commun.423, 679-683.
38. Vekrellis, K.and Stefanis, L.(2012) Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.Expert Opin.Ther.Targets 16, 421-432.
39. Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N.and Rubinsztein, D.C.(2003) Alpha-Synuclein is degraded by both autophagy and the proteasome.J.Biol.Chem.278, 25009-25013.
40. Weidenfeld-Baranboim, K., Koren, L.and Aronheim, A.(2011) Phosphorylation of JDP2 on threonine-148 by the c-Jun N-terminal kinase targets it for proteosomal degradation.Biochem.J.436, 661-669.
41. Yamauchi, J., Torii, T., Kusakawa, S., Sanbe, A., Nakamura, K., Takashima, S., Hamasaki, H., Kawaguchi, S., Miyamoto, Y.and Tanoue, A.(2010) The mood stabilizer valproic acid improves defective neurite formation caused by Charcot-Marie-Tooth disease- associated mutant Rab7 through the JNK signaling pathway.J.Neurosci.Res.88, 3189-3197.